Articles tagged with Immunotherapy
Researchers developed a human pancreatic cancer fibrotic barrier model to assess treatment strategies and test efficacy of therapeutic interventions. Inhibition of ROCK2 pathway resulted in reduced ECM remodeling and improved tissue permeability for drugs, highlighting its potential for enhancing drug delivery in PDAC.
Researchers identified two groups of follicular helper lymphocytes that produce different types of antibodies in response to virus infections and allergies. This discovery could lead to new treatments for allergy diseases without affecting immune responses to infections.
The NADINA trial found that 59% of patients responded well to neoadjuvant immunotherapy before surgery, allowing them to forgo adjuvant treatment. This treatment approach also showed rapid effects, with 95% of patients remaining tumor-free after just six weeks.
Researchers at University of Turku have discovered a novel RNA that controls the development and function of regulatory T cells. This finding may enable the development of precision medicine treatments for autoimmune diseases and cancer.
A new type of immunotherapy has been developed to treat bone cancer osteosarcoma, with promising preclinical results in mice. The treatment uses gamma-delta T cells, which are less well-known immune cells that can be engineered to target tumours.
A new study published in Nature Biomedical Engineering shows that targeted cancer treatment using antibody-displaying extracellular vesicles reduces tumour growth and improves survival in mice. The treatment has the potential to be used against other diseases and cancer types, offering a more effective and fewer side effects compared t...
A Cleveland Clinic-led team of scientists discovered that protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The interaction between VISTA and a newly discovered inhibitory receptor LRIG1 suppresses T cell replication, survival, and function.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
Researchers from Wyss Institute and Harvard University developed a biomaterial vaccine that enhances and sustains lymph node expansion, leading to more effective anti-tumor responses. The vaccine formulation, based on microscale mesoporous silica rods, reprograms antigen-presenting cells to orchestrate complex immune responses.
The Ottawa Hospital is receiving a $59 million grant to boost Canada's capacity for life-saving biotherapeutics, including vaccines, gene therapies, and cell therapies. The funding will support the construction and operation of a world-class biomanufacturing facility at its new campus.
Researchers from Scripps Research have enhanced an existing immunotherapy by removing the sugar coating surrounding solid tumors, allowing T cells to more effectively kill tumor cells. The tweak improves T-cell killing of tumor cells in mouse models, with promising results for treating solid tumors.
The McMaster University research team created the first-ever guidelines for preparing families to build their child's tolerance to common food allergens through oral immunotherapy. The guidelines, published in the Journal of Allergy and Clinical Immunology, standardize the preparation process and provide a consent form template.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
Researchers have demonstrated that attaching 'empty' backpacks to neutrophils activates them against cancer. The treated neutrophils infused into mice with cancer activated other immune cells and reduced tumor size. This technique is attractive as a 'drug-free' cell therapy for cancer.
Researchers have developed a novel immunotheraphy targeting macrophages to induce tolerance in type 1 diabetes, demonstrating its potential as a curative treatment. The therapy also shows promise for other autoimmune diseases, with results suggesting no impact on the immune system's ability to capture and process liposomes.
Researchers investigated the role of long-lived plasma cells in COVID-19 infection, finding deficient generation of spike-specific antibodies. The study suggests that inadequate long-lived plasma cell production may be responsible for short-lived protective antibody responses to SARS-CoV-2.
The tumor microenvironment (TME) is a complex ecosystem surrounding tumors that impacts tumor development, metastasis, and responses to therapies. The review highlights potential therapeutic targets modulating TME components, including immune cells, stromal cells, and ECM proteins, to inhibit tumor progression.
A new study from the University of British Columbia has found that sublingual immunotherapy (SLIT) is safe and effective for older children with multiple food allergies, who cannot risk consuming allergens orally. The treatment involves placing smaller amounts of food allergens under the tongue, allowing patients to build up their resi...
The American Academy of Otolaryngology has released a new clinical practice guideline supporting clinicians with evidence-based recommendations on immunotherapy for inhalant allergies. The guideline provides 12 key action statements to guide treatment, aiming to optimize patient care and reduce unnecessary variation in management.
A recent study by Cold Spring Harbor Laboratory researchers reveals that chronic stress can increase cancer's ability to spread. By mimicking chronic stress in mice with cancer, the team discovered that stress causes neutrophils to form sticky web-like structures called NETs, making body tissues more susceptible to metastasis.
Researchers have found a new potential therapeutic target for autoimmune diseases such as lupus and multiple sclerosis by identifying an overlooked sequence in the IκBζ protein. This sequence, known as the OCA peptide, can activate key proteins in immune cells and may help reeling in immune cells gone haywire.
Researchers found that widely used machine learning tools produce biased results for immunotherapy research, as they rely heavily on datasets from higher-income communities. This can lead to ineffective treatments for lower-income populations. The study highlights the need for accurate and unbiased data in machine learning models.
A new study has identified a genetic marker that can predict which patients are likely to respond to immunotherapy in various types of cancer. Tumors with high intragenic rearrangement (IGR) burden, which indicates cryptic structural rearrangements of the genetic code, may respond better to immunotherapy.
A new clinical trial demonstrates a small reduction in the latent reservoir of HIV-infected cells using a combination of vorinostat and immunotherapy. While the results are promising, further research is needed to create more effective approaches to flush out the virus and attack it when it emerges from latency.
Researchers discovered that VISTA induces immune suppressor cells called myeloid-derived suppressor cells (MDSCs) through a feedback loop involving STAT3 and polyamines. This pathway has high translational impact for several human cancers, offering promising drug targets.
A systematic review found that female individuals and caregivers tend to report a greater impact of food allergy on health-related quality of life. Additionally, males may experience more improvements in quality of life following immunotherapy for food allergy.
Researchers found that tumors with preexisting immune cell networks were most primed to respond to adoptive T cell therapy, and patients whose tumors featured such networks responded best to treatment. The study provides a step towards identifying patients who are likely to benefit from personalized immunotherapies.
Senescent tumour cells generated by chemotherapy can create an environment that helps tumour cells escape treatment. Eliminating these cells with immunotherapy boosts the effectiveness of chemotherapy.
Researchers have discovered that CAR T cells can be repurposed to target senescent cells, which accumulate with age and cause inflammation. This breakthrough offers a promising alternative to existing treatments, which often require repeated administration.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
Researchers uncover a link between hyperactive Rac2 and human immune deficiency, shedding light on a mysterious condition. They also find promise in using cellular cannibalism to enhance cancer treatment.
A Stanford University study reveals that ENPP1 is produced by both cancer cells and healthy cells around tumors, with high levels linked to immunotherapy resistance and metastases. Researchers found that targeting ENPP1 could improve patient responses to existing medicines and help clinicians better predict patient outcomes
A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.
A world-first human trial shows that a commonly prescribed rheumatoid arthritis drug can safely and effectively preserve the body's own insulin production and suppress the progression of type 1 diabetes. The drug, baricitinib, was found to be effective in maintaining insulin production in people who initiated treatment within 100 days ...
Researchers discovered distinct mechanisms controlling different types of immune cells and found a way to selectively eliminate 'problematic' cells driving autoimmune disorders. This breakthrough offers precise targets for potential treatment strategies, potentially revolutionizing the way we treat skin conditions.
Researchers are exploring new ways to fight metastasis, including the use of bacteria to activate a defensive response against cancer. Stress and changes in circadian rhythms have also been linked to metastasis, suggesting that these factors may be targets for prevention or treatment.
Researchers have successfully used a specially formulated toothpaste for Oral Mucosal Immunotherapy (OMIT) to desensitize adults with peanut allergies. The study showed that 100% of participants consistently tolerated the highest dose without severe reactions, and 97% adhered to treatment.
Maintenance immunosuppressive drugs linked to increased COVID-19 hospitalization risk in solid organ transplant patients. Clinicians treating transplant recipients should consider these findings for epidemic-related decisions.
Researchers found that beta-blockers can revive exhausted killer T cells, making them better cancer fighters. The study discovered a link between the sympathetic stress response and immune system response to cancer.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
A recent study found that ChatGPT scored 9/10 in accuracy for debunking Covid-19 vaccine myths, making it a reliable source of non-technical information. The AI tool's responses were accurate in addressing both true and false contraindications, but highlighted potential concerns over changes in answers over time.
Researchers at Gladstone Institutes identified conditions that enable gamma delta T cells to recognize cancer cells by disrupting energy production and causing cellular stress. This insight suggests that therapies manipulating butyrophilin abundance on the surface of cancer cells could boost gamma delta T cell effectiveness.
A recent case study highlights the challenges faced by families seeking venom immunotherapy for fire ant allergies, particularly in low-income communities. Despite proven safety and effectiveness of treatment, access remains a significant issue due to transportation barriers, lack of childcare, and work constraints.
A new study published in BMJ Oncology has found that relatively short-term use of immunosuppressant medications to control inflammatory diseases is not associated with an increased risk of developing cancer. The research included over 10,000 participants and tracked their cancer incidence for an average of 10 years.
Researchers have developed an oncolytic virus that can 'warm up' cold tumors and improve immunotherapy outcomes. The virus was engineered to carry a gene encoding a TGF-β inhibitor, which greatly increased survival rates in mice with aggressive melanoma and other cancers.
Researchers found that ranolazine, a heart medication, slows down tumor progression and increases visibility of melanoma cells to the immune system. This combination could improve response rates for immunotherapies in patients with melanoma.
Research suggests gut microbiota plays a crucial role in shaping immunotherapy response, with alterations contributing to cancer progression. The study aims to discuss the effect of microbiota on cancer immunotherapy and potential applications for improving treatment outcomes.
Researchers discovered that STING, a critical immune regulator, can act as an ion channel to control immune responses. This new function allows STING to translate danger signals into ion flow, activating various defense mechanisms.
The IBS-KAI Conference will focus on viral diseases and immunology, featuring over 20 international experts. The conference aims to prepare for responses to future infectious diseases, including those with pandemic potentials.
A study published in Cancers found that a combination of radiotherapy followed by immunotherapy is effective against oral malignant melanomas in dogs. The treatment strategy increased overall survival time compared to immunotherapy alone. Researchers are now exploring the optimal protocol for this therapy to increase its effectiveness.
Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.
Researchers have identified a key protein in the body's innate ability to fight systemic fungal infections. The study found that C5a and its downstream effects are crucial for immune cells to clear the fungus Candida albicans when it overtakes natural defenses.
A new study found that food allergy affects all racial and ethnic groups, but is most prevalent among Hispanic, non-Hispanic Black, and Asian individuals. Food allergy rates are also lower in households with higher incomes.
A study of 17,000 people across eight African countries found a decline in vaccine confidence, particularly for COVID-19 vaccines. The drop in routine childhood vaccinations has led to six million fewer children receiving life-saving shots, putting decades of progress at risk.
The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.
A new CAR T cell design approach using machine learning and artificial intelligence is being developed to improve cancer treatment. The project aims to create a hybrid knowledge- and data-driven approach to guide the design of immunotherapeutic cells.
A year-long immunotherapy through a skin patch safely desensitized toddlers with peanut allergy, lowering the risk of a severe allergic reaction from accidental exposure. Children who originally reacted to small amounts of peanuts were able to tolerate larger quantities after completing treatment.
Researchers from Rice University and Baylor College of Medicine are developing a new 'glyco-immune' checkpoint inhibitor to train the immune system to target and kill breast cancer metastasis in bones. The therapy has shown promise in preliminary tests, including eradicating cancer in some animals.
A recent study published in the Journal of Clinical Immunology suggests that cutaquig infusions at higher infusion rates and volumes are well-tolerated and effective, with reduced infusion time, fewer injection sites, and improved compliance. The study results will be presented at the Clinical Immunology Society 2023 Annual Meeting.